Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28


Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Zahoor M, Westhrin M, Aass KR, Moen SH, Misund K, Psonka-Antonczyk KM, Giliberto M, Buene G, Sundan A, Waage A, Sponaas AM, Standal T.

Blood Adv. 2017 Dec 13;1(27):2656-2666. doi: 10.1182/bloodadvances.2017010801. eCollection 2017 Dec 26.


Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A.

Haematologica. 2017 Jul;102(7):1266-1272. doi: 10.3324/haematol.2016.160564. Epub 2017 Apr 6.


Caspase-8 regulates the expression of pro- and anti-inflammatory cytokines in human bone marrow-derived mesenchymal stromal cells.

Moen SH, Westhrin M, Zahoor M, Nørgaard NN, Hella H, Størdal B, Sundan A, Nilsen NJ, Sponaas AM, Standal T.

Immun Inflamm Dis. 2016 Jul 21;4(3):327-37. doi: 10.1002/iid3.117. eCollection 2016 Sep.


PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy.

Sponaas AM, Moharrami NN, Feyzi E, Standal T, Holth Rustad E, Waage A, Sundan A.

PLoS One. 2015 Oct 7;10(10):e0139867. doi: 10.1371/journal.pone.0139867. eCollection 2015.


Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.

Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A, Standal T.

Haematologica. 2015 Dec;100(12):e511-4. doi: 10.3324/haematol.2015.124511. Epub 2015 Aug 20. No abstract available.


The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma.

Sponaas AM, Moen SH, Liabakk NB, Feyzi E, Holien T, Kvam S, Grøseth LA, Størdal B, Buene G, Espevik T, Waage A, Standal T, Sundan A.

Immun Inflamm Dis. 2015 Jun;3(2):94-102. doi: 10.1002/iid3.53. Epub 2015 Mar 2.


Osteogenic differentiation of human mesenchymal stem cells in mineralized alginate matrices.

Westhrin M, Xie M, Olderøy MØ, Sikorski P, Strand BL, Standal T.

PLoS One. 2015 Mar 13;10(3):e0120374. doi: 10.1371/journal.pone.0120374. eCollection 2015.


gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation.

Standal T, Johnson RW, McGregor NE, Poulton IJ, Ho PW, Martin TJ, Sims NA.

J Endocrinol. 2014 Nov;223(2):181-90. doi: 10.1530/JOE-14-0424. Epub 2014 Sep 16.


Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

Olsen OE, Wader KF, Misund K, Våtsveen TK, Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, Waage A, Sundan A, Holien T.

Blood Cancer J. 2014 Mar 21;4:e196. doi: 10.1038/bcj.2014.16.


The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation.

Johnson RW, Brennan HJ, Vrahnas C, Poulton IJ, McGregor NE, Standal T, Walker EC, Koh TT, Nguyen H, Walsh NC, Forwood MR, Martin TJ, Sims NA.

J Bone Miner Res. 2014 Jun;29(6):1492-505. doi: 10.1002/jbmr.2159.


Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.

Slørdahl TS, Denayer T, Moen SH, Standal T, Børset M, Ververken C, Rø TB.

Eur J Haematol. 2013 Nov;91(5):399-410. doi: 10.1111/ejh.12185. Epub 2013 Sep 16.


Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.

Jönsson S, Standal T, Olsson B, Mellström D, Wadenvik H.

Am J Hematol. 2012 May;87(5):550-2. doi: 10.1002/ajh.23155. Epub 2012 Mar 9.


Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.

Jönsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T.

J Bone Miner Metab. 2012 Jan;30(1):119-23. doi: 10.1007/s00774-011-0323-3. Epub 2011 Oct 14.


Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.

Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, Grøseth LA, Rekvig M, Børset M, Standal T, Waage A, Sundan A.

Leukemia. 2012 May;26(5):1073-80. doi: 10.1038/leu.2011.263. Epub 2011 Sep 23. Erratum in: Leukemia. 2012 May;26(5):1154.


Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis.

Grandaunet B, Syversen SW, Hoff M, Sundan A, Haugeberg G, van Der Heijde D, Kvien TK, Standal T.

Arthritis Rheum. 2011 Mar;63(3):662-9. doi: 10.1002/art.30163.


CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis.

Nørgaard NN, Holien T, Jönsson S, Hella H, Espevik T, Sundan A, Standal T.

J Immunol. 2010 Sep 15;185(6):3131-9. doi: 10.4049/jimmunol.0903605. Epub 2010 Aug 11.


Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.

Jönsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T.

Leukemia. 2010 Jul;24(7):1357-9. doi: 10.1038/leu.2010.84. Epub 2010 May 20. No abstract available.


Serum YKL-40 and bone marrow angiogenesis in multiple myeloma.

Mylin AK, Andersen NF, Johansen JS, Abildgaard N, Heickendorff L, Standal T, Gimsing P, Knudsen LM.

Int J Cancer. 2009 Mar 15;124(6):1492-4. doi: 10.1002/ijc.24110. No abstract available.


High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients.

Mylin AK, Abildgaard N, Johansen JS, Andersen NF, Heickendorff L, Standal T, Gimsing P, Knudsen LM.

Eur J Haematol. 2008 Apr;80(4):310-7. doi: 10.1111/j.1600-0609.2007.01027.x. Epub 2007 Dec 21.


Bone disease in multiple myeloma.

Hjertner Ø, Standal T, Børset M, Sundan A, Waage A.

Med Oncol. 2006;23(4):431-41. Review.


HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A.

Blood. 2007 Apr 1;109(7):3024-30.


Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.

Hjertner Ø, Standal T, Børset M, Sundan A, Waage A.

Curr Drug Targets. 2005 Sep;6(6):701-11. Review.


Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.

Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sørensen FB, Abildgaard N.

Br J Haematol. 2005 Jan;128(2):210-7.


Role of osteopontin in adhesion, migration, cell survival and bone remodeling.

Standal T, Borset M, Sundan A.

Exp Oncol. 2004 Sep;26(3):179-84.


Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

Standal T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT, Seidel C, Baykov V, Waage A, Børset M, Sundan A, Hjertner O.

Haematologica. 2004 Feb;89(2):174-82.


Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy.

Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Børset M, Waage A; Nordic Myeloma Study Group.

Br J Haematol. 2002 Dec;119(3):672-6.


Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor.

Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Waage A, Seidel C.

Blood. 2002 Dec 1;100(12):3925-9. Epub 2002 Jul 18.


Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

Standal T, Seidel C, Hjertner Ø, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A.

Blood. 2002 Oct 15;100(8):3002-7.

Supplemental Content

Loading ...
Support Center